Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2013

01-02-2013 | Research Article

X-ray repair cross-complementing group 1 Arg399Gln gene polymorphism and susceptibility to colorectal cancer:a meta-analysis

Authors: Fu-Ren Zeng, Yang Ling, Jie Yang, Xiao-Cai Tian, Xin Yang, Rong-Cheng Luo

Published in: Tumor Biology | Issue 1/2013

Login to get access

Abstract

X-ray repair cross-complementing group 1 (XRCC1), a DNA repair enzyme, plays a crucial role in the base excision repair by generating a single nucleotide repair patch. It has been demonstrated that the XRCC1 Arg399Gln gene polymorphism was associated with variations in XRCC1 enzyme activity. The aim of this study was to quantitatively summarize the association between the XRCC1 Arg399Gln polymorphism and susceptibility to colorectal cancer (CRC). A comprehensive search of the PubMed, Embase, and China National Knowledge Infrastructure databases was conducted for studies on the association between the XRCC1 Arg399Gln polymorphism and CRC risk. Summary odds ratio (OR) with its corresponding 95 % confidence interval (95 %CI) was estimated, in a fixed-effects model or a random-effects model when appropriate, to assess the association. Totally, 26 case–control studies with 6,979 cases and 11,470 controls were included into this meta-analysis. The pooled results of total studies showed that the XRCC1 Arg399Gln polymorphism was significantly associated with increased risk of CRC in all genetic contrast models (ORA vs. G = 1.13, 95 %CI 1.03–1.23, P OR = 0.008; ORGln/Gln vs. Arg/Arg = 1.24, 95 %CI 1.04–1.46, P OR = 0.015; ORGln/Gln vs. Arg/Gln + Arg/Arg = 1.19, 95 %CI 1.03–1.38, P OR = 0.021; ORGln/Gln + Arg/Gln vs. Arg/Arg = 1.14, 95 %CI 1.02–1.28, P OR = 0.022), except for the additive contrast model (ORArg/Gln vs. Arg/Arg = 1.11, 95 %CI 0.99–1.25, P OR = 0.064). The statistically significant association between the XRCC1 Arg399Gln polymorphism and CRC risk was observed among studies with high quality and in Asians, but not in Caucasians. Sensitivity analyses by sequential omission of any individual studies further identified the significant association. Publication bias was inexistent in this meta-analysis. The meta-analysis suggests that the XRCC1 Arg399Gln polymorphism is associated with increased risk of CRC.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Schee K, Flatmark K, Holm R, Boye K, Paus E. Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients. Tumour Biol. 2012;33:73–83.PubMedCrossRef
3.
Ueno H, Mochizuki H, Akagi Y, Kusumi T, Yamada K, Ikegami M, et al. Optimal colorectal cancer staging criteria in TNM classification. J Clin Oncol. 2012;30:1519–26.PubMedCrossRef
4.
Ashktorab H, Schaffer AA, Daremipouran M, Smoot DT, Lee E, Brim H. Distinct genetic alterations in colorectal cancer. PLoS One. 2010;5:e8879.PubMedCrossRef
5.
Hirata H, Hinoda Y, Matsuyama H, Tanaka Y, Okayama N, Suehiro Y, et al. Polymorphisms of DNA repair genes are associated with renal cell carcinoma. Biochem Biophys Res Commun. 2006;342:1058–62.PubMedCrossRef
6.
Mathiaux J, Le Morvan V, Pulido M, Jougon J, Begueret H, Robert J. Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer. Mol Diagn Ther. 2011;15:159–66.PubMedCrossRef
7.
Engin AB, Karahalil B, Karakaya AE, Engin A. Association between XRCC1 ARG399GLN and P53 ARG72PRO polymorphisms and the risk of gastric and colorectal cancer in Turkish population. Arh Hig Rada Toksikol. 2011;62:207–14.PubMedCrossRef
8.
Muniz-Mendoza R, Ayala-Madrigal ML, Partida-Perez M, Peregrina-Sandoval J, Leal-Ugarte E, Macias-Gomez N, et al. MLH1 and XRCC1 polymorphisms in Mexican patients with colorectal cancer. Genet Mol Res. 2012;11:2315–20.PubMedCrossRef
9.
Zhao Y, Deng X, Wang Z, Wang Q, Liu Y. Genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 and risk of colorectal cancer in Chinese population. Asian Pac J Cancer Prev. 2012;13:665–9.PubMedCrossRef
10.
Yin G, Morita M, Ohnaka K, Toyomura K, Hamajima N, Mizoue T, et al. Genetic polymorphisms of XRCC1, alcohol consumption, and the risk of colorectal cancer in Japan. J Epidemiol. 2012;22:64–71.PubMedCrossRef
11.
Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy–Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet. 2005;13:840–8.PubMedCrossRef
12.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
13.
Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256–66.PubMed
14.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
15.
16.
Md A, J W, A T, A C, R S. Facial artery and atherosclerosis. Folia Morphol (Warsz). 1999;58:199–206.
17.
Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469. author reply 70–1.PubMedCrossRef
18.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
19.
Canbay E, Cakmakoglu B, Zeybek U, Sozen S, Cacina C, Gulluoglu M, et al. Association of APE1 and hOGG1 polymorphisms with colorectal cancer risk in a Turkish population. Curr Med Res Opin. 2011;27:1295–302.PubMedCrossRef
20.
Gil J, Ramsey D, Stembalska A, Karpinski P, Pesz KA, Laczmanska I, et al. The C/A polymorphism in intron 11 of the XPC gene plays a crucial role in the modulation of an individual’s susceptibility to sporadic colorectal cancer. Mol Biol Rep. 2012;39:527–34.PubMedCrossRef
21.
Gsur A, Bernhart K, Baierl A, Feik E, Fuhrlinger G, Hofer P, et al. No association of XRCC1 polymorphisms Arg194Trp and Arg399Gln with colorectal cancer risk. Cancer Epidemiol. 2011;35:e38–41.PubMedCrossRef
22.
Zhu C, Zhang Y, Bao Q, Xu YF, Qu LL, Tang ZP, et al. The study on the relationship between XRCC1 gene polymorphisms and the susceptibility of colorectal cancer. Chin J dig. 2011;31:450–4 [Article in Chinese].
23.
Brevik A, Joshi AD, Corral R, Onland-Moret NC, Siegmund KD, Le Marchand L, et al. Polymorphisms in base excision repair genes as colorectal cancer risk factors and modifiers of the effect of diets high in red meat. Cancer Epidemiol Biomarkers Prev. 2010;19:3167–73.PubMedCrossRef
24.
Jelonek K, Gdowicz-Klosok A, Pietrowska M, Borkowska M, Korfanty J, Rzeszowska-Wolny J, et al. Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population. J Appl Genet. 2010;51:343–52.PubMedCrossRef
25.
Wang J, Zhao Y, Jiang J, Gajalakshmi V, Kuriki K, Nakamura S, et al. Polymorphisms in DNA repair genes XRCC1, XRCC3 and XPD, and colorectal cancer risk: a case–control study in an Indian population. J Cancer Res Clin Oncol. 2010;136:1517–25.PubMedCrossRef
26.
Huang S, Yi B, Yang XH, Rui R, Miao XP. Polymorphisms of DNA repair gene XRCC1 and genetic susceptibility to colorectal cancer. Chin J Exp Surg. 2010;27:1057–9 [Article in Chinese].
27.
Curtin K, Samowitz WS, Wolff RK, Ulrich CM, Caan BJ, Potter JD, et al. Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:3384–8.PubMedCrossRef
28.
Improta G, Sgambato A, Bianchino G, Zupa A, Grieco V, La Torre G, et al. Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer: a case–control study in a Southern Italian population. Anticancer Res. 2008;28:2941–6.PubMed
29.
Sliwinski T, Krupa R, Wisniewska-Jarosinska M, Lech J, Morawiec Z, Chojnacki J, et al. No association between the Arg194Trp and Arg399Gln polymorphisms of the XRCC1 gene and colorectal cancer risk and progression in a Polish population. Exp Oncol. 2008;30:253–4.PubMed
30.
Song HN, Liu XL, Er YX, Li CH, Hou RP, Xu CQ, et al. The correlative study of the XRCC1 gene haplotype and risk of colorectal cancer in China. J Qiqihar Medi Colle. 2008; 29:2957–60. [Article in Chinese]
31.
Jin MJ, Chen K, Zhang Y, Zhang W, Liu B. Zhang YJ [Correlations of single nucleotide polymorphisms of DNA repair gene XRCC1 to risk of colorectal cancer]. Ai Zheng. 2007;26:274–9.PubMed
32.
Stern MC, Conti DV, Siegmund KD, Corral R, Yuan JM, Koh WP, et al. DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study. Cancer Epidemiol Biomark Prev. 2007;16:2363–72.CrossRef
33.
Yeh CC, Sung FC, Tang R, Chang-Chieh CR, Hsieh LL. Association between polymorphisms of biotransformation and DNA-repair genes and risk of colorectal cancer in Taiwan. J Biomed Sci. 2007;14:183–93.PubMedCrossRef
34.
Martinez-Balibrea E, Manzano JL, Martinez-Cardus A, Moran T, Cirauqui B, Catot S, et al. Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan. Oncol Rep. 2007;17:637–45.PubMed
35.
Ren Z, Fan JW, Zhou CZ, Qiu GQ, He L, Peng ZH. Association between XRCC1 SNP and susceptibility to sporadic colorectal carcinoma. Chin J Exp Surg. 2007;24:1087–9 [Article in Chinese].
36.
Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res. 2006;12:2101–8.PubMedCrossRef
37.
Skjelbred CF, Saebo M, Wallin H, Nexo BA, Hagen PC, Lothe IM, et al. Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study. BMC Cancer. 2006;6:67.PubMedCrossRef
38.
Hong YC, Lee KH, Kim WC, Choi SK, Woo ZH, Shin SK, et al. Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer. Int J Cancer. 2005;116:428–32.PubMedCrossRef
39.
Krupa R, Blasiak J. An association of polymorphism of DNA repair genes XRCC1 and XRCC3 with colorectal cancer. J Exp Clin Cancer Res. 2004;23:285–94.PubMed
40.
Abdel-Rahman SZ, Soliman AS, Bondy ML, Omar S, El-Badawy SA, Khaled HM, et al. Inheritance of the 194Trp and the 399Gln variant alleles of the DNA repair gene XRCC1 are associated with increased risk of early-onset colorectal carcinoma in Egypt. Cancer Lett. 2000;159:79–86.PubMedCrossRef
41.
Yu MW, Yang SY, Pan IJ, Lin CL, Liu CJ, Liaw YF, et al. Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst. 2003;95:1485–8.PubMedCrossRef
42.
Wang B, Wang D, Huang G, Zhang C, Xu DH, Zhou W. XRCC1 polymorphisms and risk of colorectal cancer: a meta-analysis. Int J Colorectal Dis. 2010;25:313–21.PubMedCrossRef
Metadata
Title
X-ray repair cross-complementing group 1 Arg399Gln gene polymorphism and susceptibility to colorectal cancer:a meta-analysis
Authors
Fu-Ren Zeng
Yang Ling
Jie Yang
Xiao-Cai Tian
Xin Yang
Rong-Cheng Luo
Publication date
01-02-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0581-2

Other articles of this Issue 1/2013

Tumor Biology 1/2013 Go to the issue

Research Article

LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma

Research Article

Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy

Research Article

Part II. Mitochondrial mutational status of high nitric oxide adapted cell line BT-20 (BT-20-HNO) as it relates to human primary breast tumors

Research Article

Significant association between CYP1A1 T3801C polymorphism and cervical neoplasia risk: a systematic review and meta-analysis

Research Article

CD133 induces tumour-initiating properties in HEK293 cells

Editorial

Pyruvate kinase M2 and its evolving role as a prognostic marker in systemic malignancies besides colorectal carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits